MedPath
Found 1 clinical trials|View Analysis
Sort by:

Neoadjuvant Tebentafusp for Uveal Melanoma

Phase 2
Not yet recruiting
Conditions
Locally Advanced Unresectable Uveal Melanoma
Interventions
Drug: Tebentafusp-Tebn
First Posted Date
2024-05-16
Last Posted Date
2024-10-23
Lead Sponsor
Thomas Jefferson University
Target Recruit Count
19
Registration Number
NCT06414590
Locations
🇺🇸

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath